Briacell Therapeutics Corp (CVE:BCT) traded down 7.4% during trading on Wednesday . The company traded as low as C$0.13 and last traded at C$0.13. 760,425 shares were traded during mid-day trading, an increase of 101% from the average session volume of 378,188 shares. The stock had previously closed at C$0.14.
The company has a quick ratio of 0.85, a current ratio of 0.96 and a debt-to-equity ratio of 228.18. The stock has a market cap of $19.42 million and a P/E ratio of -2.68.
Briacell Therapeutics (CVE:BCT) last posted its earnings results on Thursday, March 28th. The company reported C($0.01) EPS for the quarter.
BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing personalized treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co, Inc) in patients with advanced breast cancer.
Receive News & Ratings for Briacell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.